Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of HHT201 in Healthy Subjects
NCT03932916Phase 1Completed
- Sponsor
- Shanghai Synergy Pharmaceutical Sciences Co., Ltd.
- Start
- Jul 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of donepezil in Alzheimer's disease (AD) (3 arms), sponsored by Shanghai Synergy Pharmaceutical Sciences Co., Ltd. Primary endpoints: Maximum Plasma Concentration (Cmax) of Donepezil at 35 days, Time to Maximum Plasma Concentration (Tmax) of Donepezil at 35 days and 3 more. Started Jul 2019; status: completed.
02
Drugs
donepezil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03932916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03932916.